

	ACR 20 vs. placebo	ACR 50 vs. placebo	ACR 70 vs. placebo
RA-BUILD (n=684): Moderate-to-Severe RA in c-DMARD failures, pre-biologics			
Baricitinib 4mg QD	62% @ 12 Wks	34% @ 12 Wks	18% @ 12 Wks
	65% @ 24 Wks	44% @ 24 Wks	24% @ 24 Wks
Placebo	40% @ 12 Wks	13% @ 12 Wks	3% @ 12 Wks
	42% @ 24 Wks	22% @ 24 Wks	8% @ 24 Wks
RA-BEACON (n=527): Moderate-to-Severe RA in biologic failures			
Baricitinib 4mg QD	55% @ 12 Wks	28% @ 12 Wks	11% @ 12 Wks
	46% @ 24 Wks	29% @ 24 Wks	17% @ 24 Wks
Placebo	27% @ 12 Wks	8% @ 12 Wks	2% @ 12 Wks
	27% @ 24 Wks	13% @ 24 Wks	3% @ 24 Wks
RA-BEGIN (n=584): Moderate-to-Severe RA in treatment-naïve			
MTX	59% @ 12 Wks	33% @ 12 Wks	16% @ 12 Wks
	62% @ 24 Wks	43% @ 24 Wks	21% @ 24 Wks
Baricitinib 4mg QD	79% @ 12 Wks	55% @ 12 Wks	31% @ 12 Wks
	77% @ 24 Wks	60% @ 24 Wks	42% @ 24 Wks
Baricitinib 4mg QD + MTX	77% @ 12 Wks	60% @ 12 Wks	34% @ 12 Wks
	78% @ 24 Wks	63% @ 24 Wks	40% @ 24 Wks
RA-BEAM (n=1395): Moderate-to-Severe RA in MTX failures, pre-biologics			
Baricitinib 4mg QD	70% @ 12 Wks	45% @ 12 Wks	19% @ 12 Wks
	74% @ 24 Wks	50% @ 24 Wks	30% @ 24 Wks
HUMIRA 40mg biweekly	61% @ 12 Wks	35% @ 12 Wks	13% @ 12 Wks
	66% @ 24 Wks	46% @ 24 Wks	22% @ 24 Wks
Placebo	40% @ 12 Wks	17% @ 12 Wks	5% @ 12 Wks
	37% @ 24 Wks	19% @ 24 Wks	8% @ 24 Wks

Miprofito, CFA